BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 33505143)

  • 1. Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
    Chen LX; Zou SJ; Li D; Zhou JY; Cheng ZT; Zhao J; Zhu YL; Kuang D; Zhu XH
    World J Gastroenterol; 2020 Dec; 26(48):7664-7678. PubMed ID: 33505143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and
    Thompson SM; Suman G; Torbenson MS; Chen ZE; Jondal DE; Patra A; Ehman EC; Andrews JC; Fleming CJ; Welch BT; Kurup AN; Roberts LR; Watt KD; Truty MJ; Cleary SP; Smoot RL; Heimbach JK; Tran NH; Mahipal A; Yin J; Zemla T; Wang C; Fogarty Z; Jacobson M; Kemp BJ; Venkatesh SK; Johnson GB; Woodrum DA; Goenka AH
    Hepatol Commun; 2022 May; 6(5):1172-1185. PubMed ID: 34783177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
    Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
    J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparative study of intrahepatic cholangiocarcinoma and hepatocellular carcinoma with reference to clinical features and prognosis].
    Hu JY; Zhou HB; Liu WD; Zhang J; Hu HP; Liu J
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jul; 27(7):511-515. PubMed ID: 31357776
    [No Abstract]   [Full Text] [Related]  

  • 5. Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions.
    Chen W; Lee Z; Awadallah A; Zhou L; Xin W
    Diagn Pathol; 2020 Jul; 15(1):92. PubMed ID: 32703222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
    Julich-Haertel H; Urban SK; Krawczyk M; Willms A; Jankowski K; Patkowski W; Kruk B; Krasnodębski M; Ligocka J; Schwab R; Richardsen I; Schaaf S; Klein A; Gehlert S; Sänger H; Casper M; Banales JM; Schuppan D; Milkiewicz P; Lammert F; Krawczyk M; Lukacs-Kornek V; Kornek M
    J Hepatol; 2017 Aug; 67(2):282-292. PubMed ID: 28267620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
    Lee SD; Park SJ; Han SS; Kim SH; Kim YK; Lee SA; Ko YH; Hong EK
    Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):594-601. PubMed ID: 25475861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
    Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonorchis sinensis infection amplifies hepatocellular carcinoma stemness, predicting unfavorable prognosis.
    Lin Q; Tang Z; Qin Y; Deng X; Wei C; Liu F; Pan X; Liu D; Zhan T; Fang M
    PLoS Negl Trop Dis; 2024 Jan; 18(1):e0011906. PubMed ID: 38285640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
    Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
    Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
    Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Expression of Sonic Hedgehog Protein in Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Al-Bahrani R; Nagamori S; Leng R; Petryk A; Sergi C
    Pathol Oncol Res; 2015 Sep; 21(4):901-8. PubMed ID: 25740074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.
    Ishii T; Ito T; Sumiyoshi S; Ogiso S; Fukumitsu K; Seo S; Taura K; Uemoto S
    World J Surg Oncol; 2020 Dec; 18(1):319. PubMed ID: 33276780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in cirrhotic patients].
    Salinas M; Simian D; Carreño L; Cattaneo M; Urzúa Á; Sauré A; Lembach H; Castillo J; Díaz JC; Poniachik J
    Rev Med Chil; 2022 Nov; 150(11):1431-1437. PubMed ID: 37358168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.
    Wakizaka K; Yokoo H; Kamiyama T; Ohira M; Kato K; Fujii Y; Sugiyama K; Okada N; Ohata T; Nagatsu A; Shimada S; Orimo T; Kamachi H; Taketomi A
    J Gastroenterol Hepatol; 2019 Jun; 34(6):1074-1080. PubMed ID: 30462849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
    Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
    Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
    Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
    J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma.
    Jiao D; Li Y; Yang F; Han D; Wu J; Shi S; Tian F; Guo Z; Xi W; Li G; Zhao A; Yang AG; Qin W; Wang H; Wen W
    Clin Transl Gastroenterol; 2019 May; 10(5):1-7. PubMed ID: 31116141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
    J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.